HomeStock MarketSynairgen's stock price rises! Should I buy stocks?

Synairgen’s stock price rises! Should I buy stocks?

this Syngas (London Stock Exchange: SNG) After the establishment of the company, the stock price rose in early trading this morning Released an update About its coronavirus treatment trials.

For the past two years, the team has been testing SNG001, a preparation containing the antiviral protein interferon beta, for the treatment of viruses. In other experiments, interferon beta has been shown to help improve lung function and recovery.

The killer of the cyber security wave

Cybersecurity is booming, experts predict The cybersecurity market will reach 366 billion U.S. dollars by 2028That’s more than twice today’s!

With this growth, this North American company will become the biggest winner.

Because their patented “self-healing” technology is changing the network security landscape as we know it…

We think it may become the next famous technology success story.In fact, we think it can become so big… even Bigger than Shopify.

Click here to see how to uncover the name of this North American stock This is taking over Silicon Valley, one device at a time…

The therapy has passed the first and second phases of trials. Now, SNG001 has been recommended to enter Phase 3 trials in patients with mild to moderate Covid-19.

This progress is part of a large-scale ACTIV-2 study. It is sponsored by the National Institute of Allergy and Infectious Diseases, which is responsible for running public/private projects, accelerating Covid-19 treatment inventions and vaccines or Activs.

In addition to the plan, the company also Run your own Phase 3 researchAccording to management, the results of this trial will be announced in early 2022.

Actively move forward

In my opinion, this is undoubtedly a positive step forward for the company. Entering the Phase 3 test will only strengthen the existing data of the earlier SNG001 test. Data show that the use of this therapy can substantially improve the condition of patients with severe coronavirus.

Synairgen’s products are based on the principle of delivering SNG001 directly to the lungs. The purpose of this is to help restore or enhance the natural antiviral defense capabilities to prevent the virus from causing serious lower respiratory tract diseases.

If successful, this treatment can not only help the world fight the coronavirus, it may also help defend against other viral threats. It may also play a role in helping patients recover from different diseases. Interferon beta has been used to help MS patients. Research shows that it can also help asthmatics.

Based on these qualities, I think it is unreasonable to assume that this may eventually become an important product of Synairgen. The company must first bring the treatment to the market, which is easier said than done.

Synairgen stock price risk

Although SNG001 is in a phase 3 trial, it is still likely to prove ineffective in a larger trial group. If it does succeed in trials, it may take a while for the product to go to market.

At the same time, the company will have to try to keep the lights on. This may be the most prominent risk facing investors. If it takes longer than expected to bring SNG001 to the market, or if there are complications in the current series of trials, Synairgen may run out of funds.

In this case, it may have to ask shareholders to provide additional cash, which would dilute existing investors. There is no guarantee that it can raise funds, and in the worst case, Synairgen may go bankrupt.

Nevertheless, this is the worst-case scenario. In the best case, SNG001 may become the blockbuster of the group.

Considering these factors and today’s update, I think the company’s prospects are improving. This is why I will buy a speculative position in this stock today.

Top 5 stocks of the new “green industrial revolution”

It was released in November 2020 and there is no doubt:

Is happening.

The British government’s 10-point plan for the new “Green Industrial Revolution”.

PwC believes that this trend will cost 400 billion pounds…

…In the next 10 years, this is the situation in the UK.

Globally, the green industrial revolution may be worth trillions of dollars.

That’s why I urge all investors to read this special introduction carefully and learn how to discover 5 companies that we believe are expected to profit from this huge trend!

Visit this special “Green Industrial Revolution” demo now

Rupert Hargreaves has no position in any of the aforementioned shares. The Motley Fool UK has no position in any of the aforementioned stocks. The views expressed by the companies mentioned in this article are those of the author and may therefore differ from the official recommendations we made in subscription services such as Share Advisor, Hidden Winners and Pro. At The Motley Fool, we believe that taking into account a variety of different insights, We are better investors.

Source link


Most Popular

Recent Comments